We are live on ! Find out more
TCRT icon

Alaunos Therapeutics

121 hedge funds and large institutions have $52.9M invested in Alaunos Therapeutics in 2022 Q4 according to their latest regulatory filings, with 23 funds opening new positions, 22 increasing their positions, 31 reducing their positions, and 25 closing their positions.

New
Increased
Maintained
Reduced
Closed

2,010% more call options, than puts

Call options by funds: $5.61M | Put options by funds: $266K

0.01% less ownership

Funds ownership: 0.23%0.22% (-0.01%)

8% less first-time investments, than exits

New positions opened: 23 | Existing positions closed: 25

3% less funds holding

Funds holding: 125121 (-4)

29% less repeat investments, than reductions

Existing positions increased: 22 | Existing positions reduced: 31

50% less funds holding in top 10

Funds holding in top 10: 21 (-1)

59% less capital invested

Capital invested by funds: $129M → $52.9M (-$75.7M)

Holders
121
Holders Change
-4
Holders Change %
-3.2%
% of All Funds
1.94%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.02%
New
23
Increased
22
Reduced
31
Closed
25
Calls
$5.61M
Puts
$266K
Net Calls
+$5.35M
Net Calls Change
-$8.73M

TCRT Hedge Fund Activity: Q4 2022 in Review

121 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Alaunos Therapeutics (TCRT) for Q4 2022, worth a combined $52.9M — down 59% from $129M a quarter earlier.

Sellers outnumbered buyers: 25 funds closed out of TCRT and 23 opened new positions — a net loss of 2 holders — while 31 trimmed existing stakes and 22 added.

The largest buyer was Steel Grove Capital Advisors, adding an estimated $1.59M. The largest seller was State Street, cutting an estimated $2.32M.

  • 121 institutional investors held Alaunos Therapeutics (TCRT) as of Q4 2022, down from 125 in Q3 2022.
  • Funds reported $52.9M of Alaunos Therapeutics stock for Q4 2022, down 59% quarter-over-quarter.
  • 23 funds opened new Alaunos Therapeutics positions in Q4 2022 and 25 closed out, a net change of -2 holders.
  • The largest Alaunos Therapeutics buyer in Q4 2022 was Steel Grove Capital Advisors, an estimated $1.59M added.
  • The largest Alaunos Therapeutics seller in Q4 2022 was State Street, an estimated $2.32M sold.

Based on aggregated 13F filings for Q4 2022.